Medtronic implantable cardiac monitors
This article was originally published in The Gray Sheet
Medtronic's Reveal DX next-generation implantable cardiac monitor will debut in the U.S. the week of Dec. 17 following 510(k) clearance Nov. 21, the firm announces Dec. 12. Building on the firm's earlier generation Reveal insertable loop recorders, the advanced Reveal DX has enhanced ECG and trend data capabilities, and can monitor the heart continuously for up to three years instead of just 14 months with the old system, the company explains. Placed just under the skin in the chest area, Reveal DX has no lead wires and helps physicians to diagnose whether symptoms such as dizziness and fainting are caused by cardiovascular problems, the firm says. Medtronic's similar Reveal XT, also cleared by FDA Nov. 21, is marketed in Europe for atrial fibrillation monitoring and is expected to debut in the United States at a later date
You may also be interested in...
Pharma manufacturing is operating well below normal levels in India, disrupted by labor absenteeism and supply chain issues amid the ongoing lock-down in the country, though the government is actively engaged in addressing bottlenecks. A speedy recovery is vital not just for domestic supplies.
Moderna is pursuing a single-antigen strategy even though some of its mRNA vaccines have included multiple antigens; the SARS-CoV-2 spike protein likely provides the best antigen for developing immunity against the virus.
Latest warnings also include second and third businesses in US cannabidiol and hemp sector found making unlawful claims for treating and preventing COVID-19. Four of five firms warned apparently responded by removing violative claims from websites and social media posts.